201 related articles for article (PubMed ID: 26633590)
1. Computational Prediction and Biochemical Analyses of New Inverse Agonists for the CB1 Receptor.
Scott CE; Ahn KH; Graf ST; Goddard WA; Kendall DA; Abrol R
J Chem Inf Model; 2016 Jan; 56(1):201-12. PubMed ID: 26633590
[TBL] [Abstract][Full Text] [Related]
2. Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation.
Ahn KH; Mahmoud MM; Kendall DA
J Biol Chem; 2012 Apr; 287(15):12070-82. PubMed ID: 22343625
[TBL] [Abstract][Full Text] [Related]
3. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
[TBL] [Abstract][Full Text] [Related]
4. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from postmortem human brain.
Erdozain AM; Diez-Alarcia R; Meana JJ; Callado LF
Biochem Pharmacol; 2012 Jan; 83(2):260-8. PubMed ID: 22093909
[TBL] [Abstract][Full Text] [Related]
5. A method for parallel solid-phase synthesis of iodinated analogues of the CB1 receptor inverse agonist rimonabant.
Spivey AC; Tseng CC; Jones TC; Kohler AD; Ellames GJ
Org Lett; 2009 Oct; 11(20):4760-3. PubMed ID: 19778010
[TBL] [Abstract][Full Text] [Related]
6. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A
J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649
[TBL] [Abstract][Full Text] [Related]
7. Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gα
Porcu A; Melis M; Turecek R; Ullrich C; Mocci I; Bettler B; Gessa GL; Castelli MP
Neuropharmacology; 2018 May; 133():107-120. PubMed ID: 29407764
[TBL] [Abstract][Full Text] [Related]
8. (4-(Bis(4-fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride (LDK1229): a new cannabinoid CB1 receptor inverse agonist from the class of benzhydryl piperazine analogs.
Mahmoud MM; Olszewska T; Liu H; Shore DM; Hurst DP; Reggio PH; Lu D; Kendall DA
Mol Pharmacol; 2015 Feb; 87(2):197-206. PubMed ID: 25411367
[TBL] [Abstract][Full Text] [Related]
9. F200A substitution in the third transmembrane helix of human cannabinoid CB1 receptor converts AM2233 from receptor agonist to inverse agonist.
Shen CP; Xiao JC; Armstrong H; Hagmann W; Fong TM
Eur J Pharmacol; 2006 Feb; 531(1-3):41-6. PubMed ID: 16438957
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid CB
Chen W; Liu H; Guan H; Xue N; Wang L
Eur J Pharmacol; 2017 Nov; 814():232-239. PubMed ID: 28844874
[TBL] [Abstract][Full Text] [Related]
11. Allosteric modulators restore orthosteric agonist binding to mutated CB
Dopart R; Kendall DA
J Pharm Pharmacol; 2020 Jan; 72(1):84-91. PubMed ID: 31722122
[TBL] [Abstract][Full Text] [Related]
12. Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling.
Shore DM; Baillie GL; Hurst DH; Navas F; Seltzman HH; Marcu JP; Abood ME; Ross RA; Reggio PH
J Biol Chem; 2014 Feb; 289(9):5828-45. PubMed ID: 24366865
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors.
Reggio PH
Curr Pharm Des; 2003; 9(20):1607-33. PubMed ID: 12871061
[TBL] [Abstract][Full Text] [Related]
14. Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor.
Shim JY; Welsh WJ; Cartier E; Edwards JL; Howlett AC
J Med Chem; 2002 Mar; 45(7):1447-59. PubMed ID: 11906286
[TBL] [Abstract][Full Text] [Related]
15. Structure-Based Identification of Potent Natural Product Chemotypes as Cannabinoid Receptor 1 Inverse Agonists.
Pandey P; Roy KK; Liu H; Ma G; Pettaway S; Alsharif WF; Gadepalli RS; Rimoldi JM; McCurdy CR; Cutler SJ; Doerksen RJ
Molecules; 2018 Oct; 23(10):. PubMed ID: 30322136
[TBL] [Abstract][Full Text] [Related]
16. Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716).
van Diepen H; Schlicker E; Michel MC
Naunyn Schmiedebergs Arch Pharmacol; 2008 Oct; 378(4):345-69. PubMed ID: 18654765
[TBL] [Abstract][Full Text] [Related]
17. Computational investigation on the binding modes of Rimonabant analogs with CB1 and CB2.
Liu C; Yuan C; Wu P; Zhu C; Fang H; Wang L; Fu W
Chem Biol Drug Des; 2018 Sep; 92(3):1699-1707. PubMed ID: 29797785
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.
Jacobson LH; Commerford SR; Gerber SP; Chen YA; Dardik B; Chaperon F; Schwartzkopf C; Nguyen-Tran V; Hollenbeck T; McNamara P; He X; Liu H; Seidel HM; Jaton AL; Gromada J; Teixeira S
Naunyn Schmiedebergs Arch Pharmacol; 2011 Dec; 384(6):565-81. PubMed ID: 21947251
[TBL] [Abstract][Full Text] [Related]
19. Ligand-specific homology modeling of human cannabinoid (CB1) receptor.
Ai R; Chang CE
J Mol Graph Model; 2012 Sep; 38():155-64. PubMed ID: 23079645
[TBL] [Abstract][Full Text] [Related]
20. Structural dynamics and energetics underlying allosteric inactivation of the cannabinoid receptor CB1.
Fay JF; Farrens DL
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8469-74. PubMed ID: 26100912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]